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The human C3b/C4b receptor, or complement receptor type one (CRI)t is a
single chain membrane glycoprotein found on a variety of cell types (reviewed in
reference 1) . It isone ofa family of proteins that interacts with the two complement
proteins, C3b and C4b, which bind to immune complexes and to foreign particles.
Over 85% of the CR1 on circulating cells is located on the surface of erythrocytes,
where it can mediate the binding, processing, and transport ofC3b-coated immune
complexes . In addition, CR1 on phagocytic cells promotes endocytosis ofsmallcom-
plexes and phagocytosis of larger particles . CRI also expresses regulatory activity
in that it acts as acofactor for the factor I-mediated proteolytic inactivation ofC3b
and C4b and accelerates the decay of the classical and alternative pathway C3 con-
vertases .
The proteins that bind C3b/C4b have recently become the focus of intense in-
terest, in part because many of them (CR1, H, C4bp, CR2, and DAF) are found
at a single locus on human chromosome 1 (2-6) . They also share a common struc-
tural motifoftandemly repeateddomains of60-70 aminoacids (7) . These domains,
known as short consensus repeats (SCRs), contain a number of invariant and other
frequently conserved residues at specific positions .
Four polymorphic variants ofhuman GR1 havebeen identified at theprotein level
(8-11) . Their reduced forms are ofM r 220,000 (CR1-A), 250,000 (CRl-B), 190,000
(M-C), and 280,000 (CRl-D) . In addition to classical genetic studies (8-12), two
lines of molecular evidence suggest that each allotypic variant is generated from a
different CRl allele : (a) CRl messenger RNAs from the different variants demon-
strate size increments of -1,400 by (13, 14) ; and (b) restriction fragment-length poly-
morphisms ofCRl genomic sequences indicate chromosomal differences among the
variants in the CRl-encoding region (14) .
Recently, Klickstein et al . (15) reported cDNA sequences that encode theCOOH
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terminal 76% of the CRI-A polymorphic variant. They showed that nearly all of
this portion of the molecule is composed of SCRs and that the COOH terminus
contains a transmembrane segment and a cytoplasmic domain. In addition they
found that 21 of 23 SCRs in this region are organized in three long homologous
repeats (LHRs) of seven SCRs each.
We have isolated CRI clones from cDNA libraries of DMSO-induced HL-60 cells
(13). First, we report here the amino acid sequence of the NH2 terminal 28% of
the major polymorphic form of CR1 which we derived from one of these cDNAs .
Together, with the similarly derived sequence of Klickstein et al. (15), this completes
the primary structure of the mature protein. Second, although the NH2 terminus
of CRI is composed of a fourth LHR, we find that the first two NH2-terminal SCRs
are markedly divergent when compared with the corresponding SCRs of the other
LHRs. We hypothesize that this segment is instrumental in cofactor activity, decay
accelerating activity, and/or C3b/C4b binding, and we propose a model for the or-
ganization of CRI that is based on differences in the degree of homology within
the repeated sequences. Third, we identify an alternative polyadenylation site in
the CRI transcriptional unit, and we predict the synthesis of a secreted product.
Fourth, we report a CRl-like genomic sequence that is highly homologous to the
alternative polyadenylation site and the surrounding exons of CRl_
Materials and Methods
The isolation and characterization of pUCRI-4 has been described previously (13). The
CRI-4 insert carried by that plasmid was removed by partial digestion of pUCRI-4 with
Eco RI, isolated by standard methods (16), and joined to the sequencing vector pBSKS
(Stratagene Cloning Systems, LaJolla, CA). A series ofderivatives was constructed and DNA
sequencingwas performed using the dideoxy method of Sanger et al. (17). Analysis of the
sequence data was performed on a personal computer (AT, IBM Instruments, Inc., Danbury,
CT) using the MicroGenie (Beckman Instruments, Inc., Palo Alto, CA) program.
Cosmid libraries were constructed as outlined in reference 16, using the human cell line
EB-19 (18) as a DNA source, the pTCF vector (19), and an electrophoresis apparatus (Bulls-
eye; Hoeffer Scientific Instruments, San Francisco, CA) to fractionate by size genomic DNA
partially digested with enzyme Sau 3A . The), genomic library was that of Maniatis and col-
leagues (20),constructed with the Charon 4A vector (21) and human fetal liverDNA partially
digested with Hae III and Alu I . It was obtained through the American Type Culture Collec-
tion, Rockville, MD.
The growth ofcell lines, RNA isolation, and Northern blot construction and hybridization
have been described (13). The DNA probes were electroeluted from polyacrylamide gels and
then labeled by the oligonucleotide-priming method (22). At least 0.5 ug DNA (108 cpm)
was used for each blot. Blots were reused after brief boiling and slow cooling in 2X SSC
(16) solution and afterchecking for residual hybridization by autoradiography. Southern blots
were prepared as described in reference 16.
Results and Discussion
CRI Partial cDNA Sequence and Organization of CRI.
￿
We have previously reported
the isolation and characterization of a partial CRI cDNA (13). It encodes several
known CRI peptides and is homologous to CRI messenger RNAs on Northern blots.
We have now obtained the complete nucleotide sequence of that insert . It consists
of an open reading frame that extends 1,679 by followed by an apparently untrans-
latedregion of697 by (Fig. 1). Included in the open reading frame are the sequences
of eight peptides of the CRI protein (13, 15, 22a).HOURCADE ET AL.
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The first 16 amino acids of the open reading frame bear a strong resemblance
to a typical eukaryotic signal sequence (23), including a possible NH2/hydrophobic
boundary (immediately followingSer), ahydrophobic region (Leu-Leu-Ala-ValVal-
Val-Leu-Leu-Ala-Leu), and a typical COOH region (ProVal-AlaTrp-Gly-Gln). We
anticipate the initialmethioninecodon occurs ashortdistance upstream ofthiscoding
region. According to the "(-3, -1)" rule (23), the putative signal peptide would be
cleaved between Gly and Gln, resulting in a terminal Gln residue. Since the NH2
terminus ofthe mature CRl protein isresistant to standard biochemicalsequencing
procedures (24, 25), it is likely that the Gln is modified to pyroglutamic acid (26).
The remainder oftheopen readingframe consistsof8.5 SCRs, which arecharac-
teristic ofthe family ofproteins that interact with Cab/C4b. These repeats (see Fig.
2) are 60-70 amino acids in length and include invariant residues (four cysteines,
a glycine, and a tryptophan) as well as a number of frequently conserved ones (7,
15).
The open reading frame ends with a stop codon (TGA) at apossible 5' splice se-
quence (CAGG/GTGAGT) (27). This site is followed by an apparently untranslated
region of697 bp' with no features of SCRs discernable in any reading frame. The
sequence ends with an AATAAA polyadenylation signal (28), a sequence (CTTT
GACTGC) similar to the proposed polyadenylation consensus sequence (TTTT
CACTGC) of Benoist et al. (29), and a nine-base poly(A) tail.
Our sequence, comprising the NH2 terminal 28% of CRl, includes at its 3' end
a precise overlap of 248 base pairs with the 5' end ofthe sequence ofKlickstein et
al. (15) (Fig. 1). Merging the sequences ofour two groups leads to a CRl protein
composed of 1,998 amino acids organized into 30 SCRs followed by a transmem-
brane segment and cytoplasmic region (Fig. 3 A).
Whileeach SCR intheC3b/C4b-bindingproteinfamily exhibits, typically, 20-35%
amino acidsequence homology with any other SCR in the family, the SCRs ofCR1
exhibit an additional internal homology. As first described by Klickstein et al. (15),
CRl can be organized in tandem LHRs ofseven SCRs each (Fig. 3 B). Each LHR
is 65-90% homologous to any other LHR. Our NH2-terminal sequence extends
this model through LHRA.
With completion of the primary structure, it is apparent that the SCRs ofCRl
can also be organized in another form (Fig. 3 C). This model incorporates the ho-
mologous repetition featured intheLHRmodel(Fig. 3B)while usingdifferent degrees
of intramolecular homology as aphysical basis for assigning separate regions. The
most dramatic example is region 11, composed of 16 SCRs in LHRs A, B, and C
(SCR-3 through SCR-18). Within this region, the seven SCR repetition is dupli-
cated nearly precisely; for example, SCR 3-9 is 99% homologous to SCR 10-16,
and SCR 10-11 is 99% homologous to SCR 17-18 (Fig. 3 C). Adjacent to this lies
region III, which extends 10 SCRs (SCR-19 through SCR-28). Within this region
the seven SCR repetition isalso seen inhighly homologous degree; thus, SCR 19-21
is 91% homologous to SCR 26-28. Region II and region III have been divided be-
tween SCR-18 and SCR-19 becausethedegree ofhomology in theseven SCR repeat
unit changes at thisjuncture. SCR 12-18 is only 67% homologous to SCR 19-25.
Region 1, consisting ofSCR-1 and SCR-2, which is the NH2 terminus ofthe pro-
tein, is 61°Jo homologous to SCR-8 and SCR-9 in region 11, 61% homologous to
SCR-15 and SCR-16 in region II, and 59% homologous to SCR22 and SCR-231258
FIGURE 1.
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GATCCCTGCTGGCGGTTGTGGTGCTGCTTGCGCTGCCGGTGGCCTGGGGTCAATGCAATG
S L L A V V V L L A L P V A W G Q C N
_....-..___-....___....____......__-_,.___..__......__-..___...... +1
CCCCAGAATGGCTTCCATTTGCCAGGCCTACCAACCTAACTGATGAGTTTGAGTTTCCCA
A P E W L P F A R P T N L T D E F E F P
TTGGGACATATCTGAACTATGAATGCCGCCCTGGTTATTCCGGAAGACCGTTTTCTATCA
I G T Y L N Y E C R P G Y S G R P F S I
TCTGCCTAAAAAACTCAGTCTGGACTGGTGCTAAGGACAGGTGCAGACGTAAATCATGTC
I C L K N S V W T G A K D R C R R K S C
GTAATCCTCCAGATCCTGTGAATGGCATGGTGCATGTGATCAAAGGCATCCAGTTCGGAT
R N P P D P V N G M V H V I K G I Q F G
CCCAAATTAAATATTCTTGTACTAAAGGATACCGACTCATTGGTTCCTCGTCTGCCACAT
S Q I K Y S C T K G Y R L I G S S S A T
GCATCATCTCAGGTGATACTGTCATTTGGGATAATGAAACACCTATTTGTGACAGAATTC
C I I S G D T V I W D N E T P I C D R I
CTTGTGGGCTACCCCCCACCATCACCAATGGAGATTTCATTAGCACCAACAGAGAGAATT
P C G L P P T I T N G D F I S T N R E N
TTCACTATGGATCAGTGGTGACCTACCGCTGCAATCCTGGAAGCGGAGGGAGAAAGGTGT
F H Y G S V V T Y R C N P G S G G R K V
TTGAGCTTGTGGGTGAGCCCTCCATATACTGCACCAGCAATGACGATCAAGTGGGCATCT
F E L V G E P S I Y C T S N D D Q V G I
------------------------------------------------------------
GGAGCGGCCCCGCCCCTCAGTGCATTATACCTAACAAATGCACGCCTCCAAATGTGGAAA
W S G P A P Q C I I P N K C T P P N V E
-------------------
ATGGAATATTGGTATCTGACAACAGAAGCTTATTTTCCTTAAATGAAGTTGTGGAGTTTA
N G I L V S D N R S L F S L N E V V E F
GGTGTCAGCCTGGCTTTGTCATGAAAGGACCCCGCCGTGTGAAGTGCCAGGCCCTGAACA
R C Q P G F V M K G P R R V K C Q A L N
--------------
AATGGGAGCCGGAGCTACCAAGCTGCTCCAGGGTATGTCAGCCACCTCCAGATGTCCTGC
K W E P E L P 8 C S R V C Q P P P D V L
----------------------------- --------------------------
ATGCTGAGCGTACCCAAAGGGACAAGGACAACTTTTCACCTGGGCAGGAAGTGTTCTACA
H A E R T Q R D K D N F S P G Q E V F Y
----------- --------------------------------------
GCTGTGAGCCCGGCTACGACCTCAGAGGGGCTGCGTCTATGCGCTGCACACCCCAGGGAG
S C E P G Y D L R G A A S M R C T P Q G
--------------------------
ACTGGAGCCCTGCAGCCCCCACATGTGAAGTGAAATCCTGTGATGACTTCATGGGCCAAC
D W S P A A P T C E V K S C D D F M G Q
TTCTTAATGGCCGTGTGCTATTTCCAGTAAATCTCCAGCTTGGAGCAAAAGTGGATTTTG
L L N G R V L F P V N L Q L G A K V D F
TTTGTGATGAAGGATTTCAATTAAAAGGCAGCTCTGCTAGTTACTGTGTCTTGGCTGGAA
V C D E G F Q L K G S 8 A 8 Y C V L A G
--------------------------------------
TGGAAAGCCTTTGGAATAGCAGTGTTCCAGTGTGTGAACAAATCTTTTGTCCAAGTCCTC
M E S L W N S S V P V C E Q I F C P S P
Figure continued on facing page.
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of region III. Region IV, the last two SCRs in CR1 (29 and 30), is not a part of
the seven SCR repetition. It is 26% homologous to SCR22 and SCR23, 23% ho-
mologous to SCR15 andSCR-16,23% homologous to SCR-8and SCR9, and260 /0
homologous to SCR-1 and SCR-2.C
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CAGTTATTCCTAATGGGAGACACACAGGAAAACCTCTGGAAGTCTTTCCCTTTGGAAAAG 1260
P V I P N G R H T G K P L E V F P F G K
￿
403
- ------------------ CAGTAAATTACACATGCGACCCCCACCCAGACAGAGGGACGAGCTTCGACCTCATTGGAG 1320
A V N Y T C D P H P D R G T S F D L I G
￿
423
-----------------------------------------------------------
AGAGCACCATCCGCTGCACAAGTGACCCTCAAGGGAATGGGGTTTGGAGCAGCCCTGCCC 1380
E S T I R C T S D P Q G N G V W S S P A
￿
443
--------------
￿
F
CTCGCTGTGGAATTCTGGGTCACTGTCAAGCCCCAGATCATTTTCTGTTTGCCAAGTTGA 1440
P R C G I L G H C Q A P D H F L F A K L
￿
463
AAACCCAAACCAATGCATCTGACTTTCCCATTGGGACATCTTTAAAGTACGAATGCCGTC 1500
K T Q T N A S D F P I G T S L K Y E C R
￿
483
CTGAGTACTACGGGAGGCCATTCTCTATCACATGTCTAGATAACCTGGTCTGGTCAAGTC 1560
P E Y Y G R P F S I T C L D N L V W S S 503
--------------------------
CCAAAGATGTCTGTAAACGTAAATCATGTAAAACTCCTCCAGATCCAGTGAATGGCATGG 1620
P K D V C K R K S C K T P P D P V N G M
￿
523
TGCATGTGATCACAGACATCCAGGTTGGATCCAGAATCAACTATTCTTGTACTACAGGGT 1680
V H V I T D I Q V G S R I N Y S C T T G
￿
543
GAGTTGGCAGCAACATCTCTTGGTTTAAGAGTTCCAGCACAGCGATAGTACTTTCTAGCC 1740
s
ACATCTCAGCAAGGAAACTAGGCTATTGCCACCTGCTCTTAAGAGGCTTGAACACAGGTG 1800
TTAACTCCTGATTGAAATGAACAAAGATAGGAGAAGATTAGGGGGAAAATCTGTATCCTT 1860
GCTGGAAACCAGGGCAGTGCACATATAAGAGTATGCTGTTCACTGGATGGGAAAGAAAAA 1920
AACTTAGAAGTGTAGTAGTCAAAGCACACAAACAACCCTAACCCAGAGTAGACATTGCTG 1980
GAAGAAAGGGAAGACCATGTAGCAGCTGTGTGAGAGAATGAATCTTAATGATAACAGCAT 2040
GATCCCTTGCTAGGGCTGCCATCAAAAAGTACAGGCCTTCCTCGTTTTATTGTACTTCGC 2100
AGATGTTATGCTTTTTACAAATTGAACGCTTGTGGGAACGCTGTGTAAGCATGTTCGTCG 2160
GCATCATTTATCCAACAGCGTGTGTTGACTTCGTGTCTCTGTGTAGCATTTTGATTATTC 2220
-TCACAGTATCCCAGATGTTTTCATTATTATCATGTCTGTGATAGTGATCTGTCATCAGTG 2280
ATCTTTGATGTTACTATTGTCATTGTTTGGGGTCCCTACGAACTGCACCCATATAAGACA 2340
GAAAACTTAATCAATAAATGTGCGTGCTTTGACTGCAAAAAAAAA 2385
FIGURE 1.
￿
Complete nucleotide sequence ofCRl cDNA insert and derived aminoacid sequence.
Indicated are the signal peptide region (wavy line), known CR1 peptide sequences (broken line),
the5'donor splice sequence (overlined), andtheAATAAA polyadenylation signal (overlined). Arrows
mark the region that overlaps the 5' end of the partial CRl sequence described by Klickstein
et al. (15). Also shown is a schematic of the insert and a summary of the sequencing strategy
used. These sequence data have been submitted to the EMBL/GenBank Data Libraries under
the accession number Y00812.
FIGURE 2.
￿
Alignment of the SCRs in the amino acid sequence derived from the CR1 cDNA
insert. The invariant residues are boxed anda consensus sequence, which indicates both the in-
variant and the frequently conserved residues, is shown below.
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￿
Schematic representation of CR1.
(S) Signal peptide; (TM) transmembrane
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The complex homologies among the SCRs in CRI suggest specific evolutionary
relationships. The arrangement of the first 28 SCRs into LHRs implies that this
region arose by duplication of a common seven SCR ancestral unit (15). Once mul-
tiple LHRs were established, however, additional events would have been required
to maintain the strict repetition in regions II and III. Highly homologous sequences
in CR1, such as those seen in regions II and III, could be established by duplication
andthen maintained by unequalcrossoverand/or gene conversion (13, 15). Unequal
crossover in region I and/or III could lead to the polymorphic variants seen in CRI
(13-15). Region I apparently diverged from within the LHR organization, avoiding
the process oftandem evolution so apparent in the adjacent areas. Region IV is not
part of the LHR organization and couldhave been a contemporary of the proposed
seven SCR ancestral unit or it could have appeared afterwards.
The divergence of sequence found in region I is of particular interest because,
by analogy with H, another member of the C3b/C4b-binding superfamily, this re-
gion is the likely location of several functional sites. The evidence suggests that it
is the NH2 terminal five or six SCRs (out of total of 20 SCRs) of H that carry C3b-
bindingdomains as well as cofactor activity (30, 31). In addition, both H and C4bp
are thought to be highly elongated, semi-rigid structures (32-34), and electron mi-
croscopic analysis has shown that C4b attaches near the tips of the C4bp tentacles
(33). Thus, at one extreme, the NH2-terminal region of CRI could be involved in
cofactor activity, decayaccelerating activity, andC3b/C4bbindingwhiletheremainder
of the protein would form an arm protruding from the cell surface. Experiments
with proteolytic fragmentsof C4bp have shown, however, that binding and cofactor
activity may be assigned to different internal SCRs (35) . Therefore, the active sites
in CRI may be more evenly distributed; for example, monovalent functions could
be mediated at the NH2 terminus in region I and near the cell membrane in re-
gion IV, while multivalent functions could be mediated by the internal regions II
and III. It is also possible that each separate homology region constitutes a separate
functional domain. In any case, the unique role of the N112-terminal region in the
function of CRI postulated here would be a selective force instrumental in main-
taining the divergence of region I from the adjacent regions.
Alternative Polyadenylation in the CRI Transcriptional Unit.
￿
The open reading frame
found in our derived sequence terminates at a stop codon nested within a 5' donor
splice sequence (CAGG/G7GAGT) and the cDNA ends with apolyadenylationsignal
and a poly(A) tail. Since the composite sequence of Klickstein et al. (15) extendsthe open reading frame well beyond this point, it is possible that the end of our open
reading frame corresponds to an exon/intronjunction in the CRl gene. By this model,
our cDNA clone would have been derived from an alternatively processed CRI tran-
script, truncated at an alternative polyadenylation site located in the adjacent intron
(Fig. 4).
The most straightforward means of testing this hypothesis is to compare this part
ofthe CRI gene with the cDNA. If correct, there must be a corresponding genomic
sequence that extends from the coding region for the N112-terminal half of the SCR
9, through the putative exon/intron junction, and the putative intron sequence to
the proposed polyadenylation site where divergence from the cDNA must occur.
To this end we generated a 586-bp DNA restriction fragment that lies entirely within
the proposed intron sequence (cDNA by 1,799-2,385 ; Fig. 1). Genomic Southern
hybridization using this fragment as probe yielded a pattern indicating at least two
highly related genomic copies and several distantly related sequences (Fig. 5).
Screening four cosmid libraries and two .% genomic libraries with our 586-bp probe,
we isolated three clones. These clones defined two nonoverlapping genomic regions.
Further analysis suggests that together they represent the genomic regions that bear
the most homology to our probe (Fig. 5).
DNA sequencing of one of these genomic regions, found on a X genomic clone,
yielded a segment with 99% homology to part of the cDNA sequence (Fig. 6), in-
cluding a potential exon encoding the NH2-terminal half of SCR-9 followed by the
putative intron in our cDNA clone, divergence at the proposed polyadenylation site,
and a potential exon encoding the COON-terminal half of SCR-9 found in non-
truncated cDNAs (15). Two mismatches in the translated region, however, found
in the COOH-terminal half of the SCR, are consistent with the published CRI SCR16
sequence, which differs from SCR-9 only by these same base pairs. A third mis-
match, found in the N112-terminal half of the SCR (Fig. 6), is not found in the
known SCR-9 or SCR-16 cDNA sequence. It is most likely a polymorphic variation,
since this clone was isolated from a different genetic source than the cDNAs. Thus,
although we cannot rule out the possibility of a separate gene, this first genomic
region most likely carries the two exons encoding CRl SCR-16 and the accompanying
intron.
The second genomic region, found on two different cosmids, was also sequenced
(Fig. 6). It, too, contains extensive homology to our cDNA, including a potential
exon encoding a sequence similar to the NH2-terminal half of SCR-9/SCR-16, and
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FIGURE 4.
￿
Proposed model of
alternative polyadenylation and
RNA splicing in the CRI tran-
scriptional unit and the predict-
ed polypeptide products. (S)
signal peptide; (C) transmem-
brane region and cytoplasmic
domain.1262
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FIGURE 5 .
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(A) Southern blot of
EB19 genomic DNA using a
584-bp probe . 5 wg DNA was
cut with Eco RI (lane 1), Eco
RV (lane 2), Dra I (lane 3), Ssp
I (lane 4), Hind III (lane 5), and
Barn HI (lane 6) . All lanes were
from the same 1% agarose gel .
Exposure was overnight . (B)
Southernblot ofcloned genomic
DNA . X genomic clone 1 (lane
1), cosmid 4 (lane 2), and
cosmid 5 .1 (lane 3) were cut with
Barn HI and run on a similar
gel as in A . Southern blot was
hybridized to the same probe
and exposure was overnight .
Comparison with size markers
(shown on left of A) in each gel
showed that Bam HI fragments
from the clones in B were ofthe
same mobility as the major
bands in genomic Barn HI frag-
ments in A, lane 6 (see ar-
rowheads) .
the correspondence continuesthrough the apparently untranslated region with diver-
gence at the proposed polyadenylation site . It also contains a potential exon encoding
asequence similar to the COOH-terminal half ofSCR-9/SCR-16 . The homologies,
however, averaged 95% at the nucleotide level . Additional sequencing (unpublished
data) revealed a number of possible exons that together exhibit similar homology
to most of the NH2-terminal coding region of CRl. Because the homology at the
amino acid level averages 90%, we conclude that this sequence is not part of the
CRl gene, but from a highly related genomic region . It is likely to be the same re-
gion observed by Wong et al . (36), since it exhibits a similar restriction pattern .
The genomic sequences we have found lend strong support to our proposal of
alternative polyadenylation in the CRl transcriptional unit . As already described,
thecDNA ofCR1 iscomposed oflonghomologous repeats of seven SCRs withSCR16
differing from SCR-9 by only 2 bp . Previous work suggests that this homology ex-
tends to the genomic level (14) . Thus any comparison using the SCR-16 coding re-
gion should also be valid for the SCR-9 coding region . In ourCRl genomic clone
(as well as our CRl-like genomic clone), the sequence that encodes the N112-
terminal half ofSCR-16 is interrupted by an exon/intron junction at the same site
as the SCR-9 sequences in our cDNA, continues with sequence nearly identical to
the putative intron in the cDNA, and diverges from thecDNA sequence at the pro-
posed polyadenylation site . This structure is predicted for SCR-9 coding region by
the alternative polyadenylation hypothesis (Fig . 4) . No otherRNA processingwould
be necessary to generate the truncated cDNA .
Northern Blot Analysis.
￿
Several DNA fragments were generated from ourcDNACRI GENOMIC SEQUENCE
￿
CATTTTCTTTCCCACAG/GTLkATCATGTA
TRUNCATED cDNA
￿
CAAAGATGTCTGTAAAC/
CR1-LIKE GENOMIC SEQUENCE
￿
-----------------/--G---------
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FIGURE 6.
￿
Comparison ofpor-
tions of the CRI genomic se-
quence with the CRI cDNA
and the CR1-like genomic se-
quences. Relative differences
between the CRI clone andthe
cDNAsand the CR1-like clone
are noted. Parenthesis indicate
a missing base. Diagonal slash
indicates junctions between
exons and introns. The se-
quence of the nontruncated
cDNA is taken from reference
15. Sequencing ofthe genomic
clones was performed with the
aid of synthetic oligonucleotide
primers generated from the pre-
viously determined cDNA se-
quences. These sequence data
have been submitted to the
EMBL/GenBank Data Librar-
ies under the accession number
Y00812 .
clone and used to probe poly(A)-containing RNA isolated from HL-60 cells and
from EBVtransformed lymphocytes. The 586-bp probe derived from the untrans-
lated portion ofthe cDNA and used in the Southern blots shown in Fig. 5 was also
homologous to several RNA species ranging in size from 3.0 to 4.4 kb (Fig. 7 B).
As expected, it did nothybridize to the longer RNA species (7.3-11.6 kb, depending
on the allotype) believed to encode the full-length CRI receptor (11, 12, 17). That
isbecause the intron sequence would be removed in the splicing thatjoins the RNA
30 AAACTCCTCCAGATCCAGTGAATGGCATGGTGCATGTGATCACAGACATCCATGTTGGAT
G
------------T______________-____________________-__----____-
90 CCAGAATCAACTATTCTTGTACTACAGG/GTGAGTTGGCAGCAACATCTCTTGGTTTAAG
149 AGTTCCAGCACAGCGATAGTACTTTCTAGCCACATCTCAGCAAGGAAACTAGGCTATTGC
--------------A___C___C-----------------G--------------G_--_
209 CTACCTGCTCTTAAGAGGCTTGAACACAGGTGTTAACTCCTGATTGAAATGAACAAAGAT
( )
269 AGGAGAAGATTAGGGGGAAAATCTGTATCCTTGCTGGAAACCAGGGCAGTGCACATATAA
------------------------A_____-_____________________________
329 AGAGTATGCTGTTCACTGGATGGGAAGGAAAAAAAATTAGAAGTGTAGTAGTCAAAGCAC
( ) A~
_T-------C------------------------------G___A_______________
389 ACAAACAACCCTAACCCAGAGTAGACATTGCTGGAAGAAAGGGAAGACCATGTAGCAGCT
----------------------------------------------GG_____-__--_-
449 GTGTGAGAGAATGAATCTTAATGATAACAGCATGATCCCTTGCTAGGGCTGCCATCAAAA
-----------CA------------------------G______________________
509 AGTACAGGCCTTCCTCGTTTTATTGTACTTCGCAGATGTTATGCTTTTTACAAATTGAAC
----------------A--------------A---------------------------G
569 GCTTGTGGGAACGCTG TGTAAGCATGTTCGTCGGCATCATTTATCCAACAGCGTGTGTT
---------C------CAAC-------( )A_T__________________-T______-
628 GACTTCGTGTCTCTGTGTAGCATTTTGATTATTCTCACAGTATCCCAGATGTTTTCATTA
---------------------------G,-----------A---------G__________
688 TTATCATGTCTGTGATAGTGATCTGTCATCAGTGATCTTTGATGTTACTATTGTCATTGT
---------------------------T------------------------------T_
748 TTGGGGTCCCTACGAACTGCACCCATATAAGACAGAAAACTTAATCAATAAATGTGCGTG
____A____________________________________( )----------A__
808 CTTTGACTGCTCCATGGACTAGACATTCCCCTTCTGTCTCCC . . .
AAAAAAAAA
-------------------A-------------G________. . .
1 CR1 GENOMIC SEQUENCE . . .TTTCCATTTTTTGCCTTTAG/GCACCGACTC
NON-TRUNCATED cDNA SCR-9 . .AACTATTCTTGTACTACAGG/
CR1-LIKE GENOMIC SEQUENCE -----------------------/----------
31 ATTGGTCACTCATCTGCTGAATGTATCCTCTCAGGCAATACTGCCCATTGGAGCACGAAG
G-G
--------------------------------G----------------------T____
91 CCGCCAATTTGTCAAC/GTGAGTTGAA. . .
/GAATTCCTTG
__A_____________/__________,1264
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FIGURE 7 .
￿
Northern blot anal-
ysis of cell lines that express
CRl . The probe used inA was
a 257-bp DNA fragment and
the probe used in Bwas a 586-
bp fragment also used in Fig. 5 .
They were each derived from
the regions of the CRI insert
that are shown . The source of
RNAs is as described in refer-
ence 13 . (1) 4 ug DMSO-in-
ducedHL-60(CRl-A homozy-
gote) RNA; (2) 15 wg EB 19
(CRl-A homozygote)RNA; (3)
15 mg EB22 (CRl-B homozy-
gote) RNA; (4) 10 ug EB1916
(CRl-A/CRl-C heterozygote)
RNA . EB19,EB22,andEB1916
refer to EBVtransformed B
lymphocyte cell lines derived
from individuals expressing the
indicatedCRI phenotype .The
same blot was used for each
probe and exposure was 6 d .
Sizes ofthe hybridizingmRNAs
(in kb) are at left .
segments encoding the two halves of SCR-9 (Fig . 4) . In contrast, probes derived
from the translated region are homologous to both full-length and truncated CRI
mRNA (Fig . 7 A) .
The Northern blot results suggest that the CRI transcriptional unit could pro-
duce a number of truncatedRNA species . The largest ofthese species, 4 .4 kb, could
be an artifact because it migrates close to the 28S RNA band . Even so, several dis-
tinct transcripts remain . Our sequence data indicates that one of these is processed
atSCR9 . Given the sequence similarity, one might expect another alternative poly-
adenylation site in SCR-16, yielding a second truncated messenger, 1,350 bases greater
in length than the first one . Remaining messengers could be the result of additional
alternative polyadenylation sites in the same introns or multiple transcriptional start
sites . In addition, it is possible that the CR1-like genomic sequence described above
could be the source of one or more of these transcripts, since the probes used in
the Northern blots also hybridize to the CRl-like genomic region . Further work is
required to understand the source of each of theshort transcripts seen on the Northern
blots .
OurNorthern analysis yielded similar 3.0-4.4-kb species whether theRNA source
carried the CR1-A polymorphism, the CRl-B polymorphism, or both the CRl-A
and CRl-C polymorphisms, although the CRl-B transcripts were faint (Fig. 7) . This
result suggests that the CRl-A andtheCR1-B alleles may carry the same alternative
processing sites but does not preclude the possibility that CRl-C is lacking some
or all of these sites .
In our previous work (13), hybridization of poly(A)-containing mRNA to probes
encoding the CRl-translated region did reveal short species . At that time their rela-
tion to the CRI gene was not known and it was possible that they represented hy-HOURCADE ET AL.
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bridization to other members of the gene family. Only recently has it become clear
that CRl nucleotide sequences do not hybridize at high stringency to the mRNAs
of DAF and CR2 (3, 37). In adifferent report (17), hybridization of similar probes
to tonsillar RNA apparently yielded no shorter species. This could be due to the
difference in cell types.
Prediction ofa Secreted Form of CRl.
￿
The polypeptide predicted from the cDNA
clone is a signal sequence followed by the NH2-terminal 8.5 SCRs. The first eight
SCRs should retain the same functional capacity as they do in CRl since theirstruc-
ture would probably notchange. The last half-SCR segment, 35 aminoacids in length,
would not retain the conformation found in the full repeat, since it is believed that
the cysteines at position 4 and 46 and the cysteines at positions 32 and 57 arelinked
by their side chains in the repeated domains, as in 02 glycoprotein I (7, 38). The
terminal-halfSCR could be a candidate for proteolytic cleavage at the arginine or
lysine residues that immediately preceed it.
Since a short form of CRl wouldlack thetransmembranesequence and cytoplasmic
anchor found at theCOON terminus ofthe receptor (15), it would likely be secreted.
It is possible that a secreted CRI form would express complement-mediating ac-
tivity that surface-bound forms could not.
Although asecreted form related to CRI has been reported (39), it is much larger
in size than any predicted from ourwork. There have been other studies, however,
that have shown the presence of biosynthetically-labeled C3b-binding proteins of
approximately the size appropriate for a 60-kD form in HL-60 cells (see Fig. 4 of
reference 40). Alternatively, it is possible that the secreted form is not expressed at
maximal levels in cells that are producing membrane CR1 and will only be found
in other cell types, other tissues, or during specific stages of B lymphocyte develop-
ment or differentiation.
Regulation ofthe CRI Transcriptional Unitby SelectivePolyadenylation.
￿
The use of two
different processing events at an intron within SCR-2 of LHR-B appears to govern
the production of two classes of CRI messenger RNAs. Polyadenylation results in
the shortertranscripts that could direct the synthesis of secreted CRl, while splicing
is required for the production of longer transcripts that direct the synthesis of the
CRl receptor. In general, it appearsthat theaddition ofpoly(A) to Tends ofnuclear
RNAoccurs more rapidly than RNA splicing (41-44), so it is the control of polyade-
nylation at this site that probably determines the processing pathway used.
The selection of alternative polyadenylation sites within a transcriptional unit
resulting in differential gene expression occurs in the regulation of the late tran-
scriptional unit of adenovirus 2 (45) and in the tissue-specific expression of calcitonin
and calcitonin gene-related peptide (46). Moreover, it also appears in the develop-
mental progression from expression of surface IgM in B lymphocytes to the secre-
tion of IgM in mature plasma cells (47). In each of these cases, as well as that of
CR1, trans-acting factors could be involved in the selection of polyadenylation sites.
The alternative polyadenylation site in CRI could be used to regulate the ratio of
full-length messenger to truncated messenger.
Evolution ofthe C3b/C4b-binding Protein Multigene Family.
￿
As mentioned, CRI is
a member of a"superfamily" ofC3b/C4b-binding proteins, all ofwhich possess tan-
demly repeated domains like the CRl SCRs (7). Although some of the genes that
encode these proteins are located on different chromosomes, CRI is located in a1266
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cluster at q3.2 on human chromosome 1 (3) along with C4bp, H, DAF, and CR2
(2-6). Members of this "immediate" family each manifest cofactor and/or decay-
accelerating activity as well as Cab/C4b-binding capacity and include both surface
and secreted proteins (7).
Evidence is accumulating that many of the SCRs in the superfamily are each en-
coded by a single exon (7). We report exceptions to that rule in CRI (SCR-9 and
SCR-16) and the SCR-9/SCR-16 homology in the CR1-like sequence. Furthermore,
we find that the sequence of a second CRI cDNA indicates the presence of another
"split" SCR (SCR-20) in CRI and examination o£ the CR1-like genomic clone re-
veals split exons encoding the SCR-2 and SCR-6/SCR-13 homologies (unpublished
data). All of these divisions occur at the same position in the consensus sequence.
In addition, murine H and C4bp genes each code an SCR split at the same site
(48, 49). It is likely that all of these split SCRs are related through a common an-
cestor. Another split SCR is seen in the human haptoglobin sequence (50). In that
case the intervening sequence appears to occur at a different position in the con-
sensus sequence and therefore, is likely to have arisen through an independent event.
Two simple models could account for thesplit SCRs. A primordial exon encoding
an entire SCR was interrupted through transposition by an intervening sequence.
Alternatively, the primordial SCRwasencoded by two separate but adjacent exons.
Intron deletion might have led to composite ("unsplit") SCRs.
It will be of interest to learn whether other members of the Cab/C4b superfamily
carry similarly positioned introns with alternative polyadenylation sites. It has al-
ready been seen in other membersofthe superfamily (DAF and H) that alternative
RNA splicing can result in a transcript that would encode a second form (51-55).
It has been suggested, based on alternative polyadenylation in the production of
surface and secreted forms of IgM from a single transcriptional unit, that regulated
polyadenylation sitescouldhave been instrumental in the evolution of secreted anti-
bodies from surface receptors (56). It now appearspossible that alternative polyade-
nylation could similarly have been instrumental in the evolution of the family of
C3b/C4b binding proteins from a primitive receptor gene to the modern genes that
encode secreted C3b/C4b-binding proteins as well as genes that produceboth secreted
and surface forms.
Summary
The human C3b/C4b receptor or complement receptor type one (CR1) is an N200-
kD single chain membrane glycoprotein ofhuman peripheral bloodcellsthat mediates
the binding, processing, and transport of C3b-bearingimmune complexes andregu-
lates the activity of the complement cascade. Analysis of partial cDNA clones has
shown that the COOH terminus is composed predominantly of three tandemly
repeated regions of 450 amino acids each (15). In this report, we present a cDNA
sequence that encodes the NH2 terminus of CRl. It appears to have been derived
from an alternatively processed transcript, caused by polyadenylation occurring at
a site within an intron in the CRI transcriptional unit. Theresultingtruncated mes-
senger carries an open readingframethat wouldproduce a short, secreted CR1 form.
We present genomic sequences and Northern blots which support this hypothesis
and we propose that the NH2-terminal end of CRI is a likely location for activeHOURCADE ET AL.
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sites. In addition, we report evidence for a CR1-like sequence in the human genome
and we present a model for the organization of CR1.
We thank Stanley Korsmeyer and David Chaplin for their helpful reviews of the manuscript,
Lisa Westfield for synthesis of oligonucleotide primers, and Pat Parvin and Lorraine Whitely
for excellent secretarial assistance.
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